Payment overview · 2025
General Payments
$1,541.99
69 reported records · 12 companies
Healthcare provider profile · identity verified
Keith L Kidd, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHARLESTON, TN · NPI 1811168941
Verified facts
What the public records show
CMS Open Payments records show Keith L Kidd, FNP-BC received $1,541.99 in general payments during 2025 across 69 reported records.
Axsome Therapeutics, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $346.73 | 22.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $317.70 | 20.6% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $264.34 | 17.1% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $244.42 | 15.8% | 20 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $183.03 | 11.9% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.50 | 3.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.24 | 2.3% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $33.89 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.47 | 2.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.64 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.37 | 1.0% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $1.66 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,540.33 | 68 |
| Education | $1.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $264.34 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $244.42 | 20 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $183.03 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $182.32 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.90 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $164.41 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.97 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $1.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 262 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 65 |
| Lisinopril | Lisinopril | 244 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 58 |
| Alprazolam | Alprazolam | 220 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 208 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 202 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 173 | 56 |
| Omeprazole | Omeprazole | 166 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 32 |
| Furosemide | Furosemide | 131 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 22 |
| Trazodone Hcl | Trazodone Hcl | 121 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 26 |
| Metformin Hcl | Metformin Hcl | 114 | 31 |
| Pregabalin | Pregabalin | 113 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 20 |
| Potassium Chloride | Potassium Chloride | 110 | 25 |
| Losartan Potassium | Losartan Potassium | 108 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 24 |
| Ozempic | Semaglutide | 93 | 18 |
| Buspirone Hcl | Buspirone Hcl | 89 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 88 | 17 |
| Prednisone | Prednisone | 86 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 17 |
| Famotidine | Famotidine | 77 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 13 |
| Carvedilol | Carvedilol | 75 | 22 |
| Tramadol Hcl | Tramadol Hcl | 73 | 19 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 15 |
| Montelukast Sodium | Montelukast Sodium | 62 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 12 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 29 |
| Allopurinol | Allopurinol | 54 | 12 |
| Farxiga | Dapagliflozin Propanediol | 53 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Mupirocin | Mupirocin | 48 | 29 |
| Promethazine Hcl | Promethazine Hcl | 48 | 12 |
| Simvastatin | Simvastatin | 48 | 15 |
| Lorazepam | Lorazepam | 47 | 11 |
| Vascepa | Icosapent Ethyl | 47 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Azelastine Hcl | Azelastine Hcl | 44 | 24 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 29 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 13 |
| Azithromycin | Azithromycin | 34 | 29 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 11 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 16 |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Amoxicillin | Amoxicillin | 26 | 20 |
| Diazepam | Diazepam | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Colchicine | Colchicine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,541.99 · 69 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, Filspari, GVOKE HYPOPEN, Kerendia, LOREEV XR, OTEZLA, REPATHA, REXULTI, Sunosi, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error